Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a buy rating in a report published on Monday, December 25th. Zacks Investment Research currently has $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

Other equities analysts have also recently issued reports about the stock. B. Riley assumed coverage on shares of Actinium Pharmaceuticals in a research report on Wednesday, December 6th. They set a buy rating and a $2.75 price target on the stock. Maxim Group set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, November 1st. Roth Capital reaffirmed a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, HC Wainwright reaffirmed a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Five investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $3.75.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) opened at $0.73 on Monday. The firm has a market cap of $56.02, a price-to-earnings ratio of -1.55 and a beta of 41.30. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72.

COPYRIGHT VIOLATION NOTICE: “Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Buy” by Zacks Investment Research” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://stocknewstimes.com/2018/01/12/actinium-pharmaceuticals-atnm-raised-to-buy-at-zacks-investment-research-3.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply